Current Issue - July 2025, Volume 19, Issue No. 2

1. Cheng H, Hao B, Sun J, Yin M. C-Terminal Cross-Linked Telopeptides of Type II Collagen as Biomarker for Radiological Knee Osteoarthritis: A Meta-Analysis. Cartilage. 2020; 11(4): 512-20. doi: 10.1177/1947603518798884
2. Heidari B. Knee osteoarthritis diagnosis, treatment and associated factors of progression: part II. Caspian J Intern Med. 2011; 2(3): 249-55.
3. Hussain A, Verma C, Kaushik LS, Singh S. Efficacy of sCOMP and sCTX-I in Diagnosis of Knee Osteoarthritis. Indian J Orthop. 2022; 56(9): 1565-71. doi: 10.1007/s43465-022-00686-5
4. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008; 9: 116. doi: 10.1186/1471-2474-9-116
5. Singh S, Jindal D, Khanna R. Can serum MMP-3 diagnose early knee osteoarthritis? J Orthop. 2023; 38: 42-6. doi: 10.1016/j.jor.2023.02.014
6. Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 2000; 43(5): 953-68. doi: 10.1002/1529-0131(200005)43:5<953::AID-ANR1>3.0.CO;2-Q
7. Dincel YM. Value of biomarkers in osteoarthritis. Intech Open. 2018: 5. doi: 10.5772/intechopen.79946
8. Rousseau JC, Delmas PD. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol. 2007; 3(6): 346-56. doi: 10.1038/ncprheum0508
9. Tanishi N, Yamagiwa H, Hayami T, Mera H, Koga Y, Omori G, et al. Usefulness of urinary CTX-II and NTX-I in evaluating radiological knee osteoarthritis : the Matsudai knee osteoarthritis survey. J Orthop Sci. 2014; 19(3): 429-36. doi: 10.1007/s00776-014-0535-1
10. Park YM, Kim SJ, Lee KJ, Yang SS, Min BH, Yoon HC. Detection of CTX-II in serum and urine to diagnose osteoarthritis by using a fluoro-microbeads guiding chip. Biosens Bioelectron. 2015; 67: 192-9. doi: 10.1016/j.bios.2014.08.016
11. Ourradi K, Sharif M. Biomarkers for diagnosis of osteoarthritis. JSM Bone Joint Dis. 2017; 1(1): 1002.
12. Sowers MF, Karvonen-Gutierrez CA, Yosef M, Jannausch M, Jiang Y, Garnero P, et al. Longitudinal changes of serum COMP and urinary CTX-II predict X-ray defined knee osteoarthritis severity and stiffness in women. Osteoarthritis Cartilage. 2009; 17(12): 1609-14. doi: 10.1016/j.joca.2009.06.001
13. Bai B, Li Y. Combined detection of serum CTX-II and COMP concentrations in osteoarthritis model rabbits: an effective technique for early diagnosis and estimation of disease severity. J Orthop Surg Res. 2016; 11(1): 149. doi: 10.1186/s13018-016-0483-x
14. Xin L, Wu Z, Qu Q, Wang R, Tang J, Chen L. Comparative study of CTX-II, Zn2+, and Ca2+ from the urine for knee osteoarthritis patients and healthy individuals. Medicine (Baltimore). 2017; 96(32): e7593. doi: 10.1097/MD.0000000000007593
15. Huang M, Zhao J, Huang Y, Dai L, Zhang X. Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis. J Orthop Translat. 2017; 13: 50-57. doi: 10.1016/j.jot.2017.06.005
16. Arunrukthavon P, Heebthamai D, Benchasiriluck P, Chaluay S, Chotanaphuti T, Khuangsirikul S. Can urinary CTX-II be a biomarker for knee osteoarthritis? Arthroplasty. 2020; 2(1): 6. doi: 10.1186/s42836-020-0024-2
17. Manicourt DH, Bevilacqua M, Righini V, Famaey JP, Devogelaer JP. Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D. 2005; 6(5): 261-71. doi: 10.2165/00126839-200506050-00002
18. Meini S, Bellucci F, Cucchi P, Catalani C, Nizzardo A, Rossi C, et al. Serum biomarkers detection clusters improve the detection of symptomatic treatment effect in knee osteoarthitis patients: the results of a phase ib/iia study with the b2 receptor antagonist fasitibant. Osteoarthritis Cartilage. 2014; 22: supplement, S63.
19. Zhijun L, Rongchun C, Feixiang L, Yaohong W, Ning L, Shufang Z, et al. Therapeutic effects of combined meloxicam and glucosamine sulfate treatment on patients with osteoarthritis, and its effect on serum CTX-U44; CTX-U45;, COMP and MMP-3. Trop J Pharm Res. 2019; 18(7): 1553-7. doi: 10.4314/tjpr.v18i7.28
20. Liem Y, Judge A, Kirwan J, Ourradi K, Li Y, Sharif M. Multivariable logistic and linear regression models for identification of clinically useful biomarkers for osteoarthritis. Sci Rep. 2020; 10(1): 11328. doi: 10.1038/s41598-020-68077-0
21. Traistaru MR, Kamal D, Maria DT, Zorila MV, Alexandru DO, Rogoveanu OC, et al. Complex evaluation in patients with knee osteoarthritis. Rom J Morphol Embryol. 2019; 60(1): 167-74.
22. Wang P, Song J, Qian D. CTX-II and YKL-40 in early diagnosis and treatment evaluation of osteoarthritis. Exp Ther Med. 2019; 17(1): 423-31. doi: 10.3892/etm.2018.6960
23. Luo Y, He Y, Karsdal M, Bay-Jensen AC. Serological CTX-II does not measure the same as urinary CTX-II. Osteoarthr Cartil Open. 2020; 2(3): 100082. doi: 10.1016/j.ocarto.2020.100082
24. Rousseau JC, Chapurlat R, Garnero P. Soluble biological markers in osteoarthritis. Ther Adv Musculoskelet Dis. 2021; 13: 1759720X211040300. doi: 10.1177/1759720X211040300
25. Hunt ER, Jacobs C, Huebner JL, Kraus VB, Lattermann C. Are serum cartilage degeneration biomarker concentrations accurate representations of the intra-articular environment of the knee? Osteoarthritis Cartilage. 2018: 26(1): S197-8.
26. Liu CX, Gao G, Qin XQ, Deng CQ, Shen XJ. Correlation Analysis of C-terminal telopeptide of collagen type II and Interleukin-1β for Early Diagnosis of Knee Osteoarthritis. Orthop Surg. 2020; 12(1): 286-94. doi: 10.1111/os.12586

Abstract   |   Reference